Australia markets open in 5 hours 18 minutes

Ocular Therapeutix Inc (0OT.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
2.9560-0.0460 (-1.53%)
As of 11:50AM CEST. Market open.
Full screen
Previous close3.0020
Open2.9700
Bid3.0080 x N/A
Ask3.0460 x N/A
Day's range2.9560 - 2.9720
52-week range2.4160 - 7.2600
Volume0
Avg. volume77
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery

    AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmologic, neurological and psychiatric disorders, today announced that the first patient has been treated in the Phase 3 registrational study in China to investigate the efficacy and safety of DEXTENZA (0.4 mg dexamethasone ophthalmic insert) in subjects following ophthalmic sur

  • GlobeNewswire

    Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

    BEDFORD, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences: H.C. Wainwright 25th Annual Global Investment ConferenceDate: Tuesday, September 12, 2023Ocular Therapeutix™ to host investor one-on-one meetingsLocation: Lotte New York Palace Hotel,

  • GlobeNewswire

    Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

    BEDFORD, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a panel at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference on Wednesday, August 16, 2023 at 11:00 AM EDT. In addition